STOCK TITAN
  1. Home
  2. Sec-filings
  3. RPID
  4. [8-K] RAPID MICRO BIOSYSTEMS, INC. Reports Material Event

Rapid Micro Biosystems (Nasdaq: RPID) grows Q2 revenue and reaffirms 2026 outlook

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Rapid Micro Biosystems reported second quarter 2026 total revenue of $8.1 million, up 10.9% from $7.3 million a year earlier. Product revenue was $5.3 million and service revenue $2.8 million. Recurring revenue rose 14.3% to $5.0 million, representing 63% of total revenue, and consumable revenue grew more than 20% year over year. The company placed four new Growth Direct systems, completed nine validations and reached a milestone of 200 Growth Direct systems placed globally.

Total cost of revenue declined to $6.8 million, driving record second-quarter gross margin of 15.0%, up from 3.8% in the prior-year quarter. Operating expenses increased 8.9% to $13.5 million. Net loss was $12.9 million, or $0.27 per share, and non-GAAP adjusted EBITDA loss was $10.3 million. Cash, cash equivalents and short-term investments were approximately $20 million as of June 30, 2026. The company reaffirmed full year 2026 guidance for total revenue of $37.0–$41.0 million and gross margin of approximately 20%, and raised full year system validation guidance to at least 27.

Positive

  • Second quarter 2026 revenue increased 10.9% to $8.1 million, with recurring revenue up 14.3% to $5.0 million and record second-quarter gross margin of 15.0%, up from 3.8% a year earlier.

Negative

  • The company remains loss-making, with Q2 2026 net loss of $12.9 million and cash, cash equivalents, investments and restricted cash declining to $20,050 thousand from $38,580 thousand at December 31, 2025.
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Total revenue Q2 2026 $8.1 million Increased 10.9% from $7.3 million in the second quarter of 2025
Gross margin Q2 2026 15.0% Record second-quarter gross margin, up from 3.8% in Q2 2025
Net loss Q2 2026 $12.9 million Net loss per share was $0.27, same as Q2 2025
Non-GAAP adjusted EBITDA loss Q2 2026 $10.3 million Compared with a $10.1 million loss in the second quarter of 2025
Cash, cash equivalents and short-term investments approximately $20 million Balance as of June 30, 2026
Total operating expenses Q2 2026 $13.5 million Increased 8.9% from $12.4 million in the second quarter of 2025
2026 revenue guidance $37.0–$41.0 million Reaffirmed full year 2026 total revenue guidance range
2026 gross margin guidance approximately 20% Expected full year 2026 total gross margin percentage
recurring revenue financial
"Recurring revenue increased 14.3% to $5.0 million"
Revenue that a company expects to receive on a regular, predictable basis from ongoing sources such as subscriptions, service contracts, or repeat customer purchases. It matters to investors because it provides steadier cash flow and makes future earnings easier to forecast—like a landlord collecting monthly rent instead of one-off sales—supporting higher valuations and lower risk when those payments are reliable and customers tend to stay.
non-GAAP adjusted EBITDA financial
"Unaudited net Loss to Non-GAAP Adjusted EBITDA Loss Reconciliation"
Non-GAAP adjusted EBITDA is a measure of a company's profitability that shows earnings before interest, taxes, depreciation, and amortization, with certain adjustments made to exclude irregular or non-recurring expenses and income. It provides a clearer picture of ongoing operational performance by filtering out items that might distort the core business results. Investors use it to better compare how well different companies are performing without the noise of one-time events.
deferred revenue financial
"Deferred revenue | 5,508 | | | 4,734"
Cash a company has already received for goods or services it has promised but not yet delivered; it's recorded as a liability because the company still owes that product, service, or future revenue recognition. For investors, deferred revenue signals upcoming work or deliveries that will convert into reported sales over time and affects short-term obligations, cash flow quality, and how quickly a firm can grow recognized revenue—think of it like prepaid subscriptions or gift cards a business must honor later.
warrant liability financial
"Warrant liability | 68 | | | 186"
Warrant liability is the financial obligation a company records when it grants warrants—special options giving the holder the right to buy company shares at a set price in the future. It matters to investors because changes in this liability can affect a company's reported earnings and overall financial health, similar to how a pending contract can influence a company's future value.
microbial quality control technical
"automated microbial quality control (“MQC”) testing workflows"
Total revenue Q2 2026 $8.1 million Increased 10.9% from $7.3 million in Q2 2025
Gross margin Q2 2026 15.0% Up from 3.8% in Q2 2025
Net loss Q2 2026 $12.9 million Compared with $11.9 million in Q2 2025
Non-GAAP adjusted EBITDA loss Q2 2026 $10.3 million Compared with $10.1 million loss in Q2 2025
Cash, cash equivalents and short-term investments approximately $20 million Balance as of June 30, 2026
Guidance

Reaffirmed full year 2026 total revenue guidance of $37.0–$41.0 million, gross margin of approximately 20%, 30–38 Growth Direct system placements, and at least 27 system validations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What were Rapid Micro Biosystems (RPID) Q2 2026 revenues?
Rapid Micro Biosystems reported Q2 2026 total revenue of $8.1 million, up 10.9% from $7.3 million in Q2 2025. Product revenue was $5.3 million and service revenue $2.8 million, reflecting growth in both system sales and services.

How did Rapid Micro Biosystems (RPID) gross margin change in Q2 2026?
Gross margin improved to a record 15.0% in Q2 2026, or $1.2 million, compared with 3.8% and $0.3 million in Q2 2025. Total cost of revenue fell slightly to $6.8 million, supporting this margin expansion.

What was Rapid Micro Biosystems (RPID) net loss and EPS in Q2 2026?
Net loss in Q2 2026 was $12.9 million, or $0.27 per basic and diluted share, compared with a net loss of $11.9 million and the same per-share loss of $0.27 in Q2 2025, indicating continued but stable per-share losses.

What guidance did Rapid Micro Biosystems (RPID) give for full year 2026?
The company reaffirmed 2026 total revenue guidance of $37.0–$41.0 million and total gross margin of approximately 20%. It expects 30–38 Growth Direct system placements and increased its system validation target to at least 27.

How much liquidity did Rapid Micro Biosystems (RPID) have at June 30, 2026?
As of June 30, 2026, cash, cash equivalents and short-term investments were approximately $20 million. Including restricted cash and investments, cash, cash equivalents, investments and restricted cash totaled $20,050 thousand, down from $38,580 thousand at December 31, 2025.

How many Growth Direct systems did Rapid Micro Biosystems (RPID) place and validate in Q2 2026?
In Q2 2026, the company placed four new Growth Direct systems and completed nine customer system validations, versus four placements and two validations a year earlier. Cumulatively, it achieved a milestone of 200 Growth Direct systems placed globally.
0001380106false00013801062026-08-072026-08-07

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): August 7, 2026
RAPID MICRO BIOSYSTEMS, INC.
(Exact name of registrant as specified in its charter)
Delaware001-4059220-8121647
(State or other jurisdiction
of incorporation or organization)		(Commission
File Number)		(I.R.S. Employer
Identification No.)
 25 Hartwell Avenue, Lexington, MA
02421
(Address of principal executive offices)
(Zip Code)
978-349-3200
(Registrant’s telephone number, including area code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbols		Name of each exchange on which
registered
Class A Common Stock, $0.01 par value per shareRPID
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company þ
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o


Item 2.02
Results of Operations and Financial Condition.
On August 7, 2026, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its second quarter ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety.
The information furnished under Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as otherwise expressly stated in such filing.
Item 9.01
Financial Statements and Exhibits.
(d)Exhibits.
Exhibit No.Description
99.1
Press Release of Rapid Micro Biosystems, Inc., dated August 7, 2026, related to its financial results for its second quarter ended June 30, 2026.
104
Cover Page Interactive Data File (formatted as inline XBRL)


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
RAPID MICRO BIOSYSTEMS, INC.
Date: August 7, 2026By:/s/ Sean Wirtjes
Sean Wirtjes
Chief Financial Officer


Exhibit 99.1
Rapid Micro Biosystems Reports Second Quarter 2026 Financial Results
•Reports second quarter 2026 total revenue of $8.1 million, representing 11% growth compared to the second quarter of 2025
◦Achieved a significant milestone with the 200th Growth Direct system placed globally; placed four Growth Direct systems and completed nine validations in the second quarter 2026
◦Second quarter consumable revenue increased more than 20% year-over-year
◦Second quarter recurring revenue increased 14% year-over-year; comprised 63% of total revenue
•Reports record second quarter total gross margin of 15%, an increase of 11 percentage points compared to the second quarter of 2025
•Merck MilliporeSigma to host European Growth Direct Day in October 2026, supporting customer engagement, education, and commercial pipeline development across Europe
•Reaffirms full year 2026 total revenue guidance range of $37.0 million to $41.0 million, including 30 to 38 Growth Direct system placements
•Reaffirms full year 2026 gross margin percentage guidance of approximately 20%, with second half 2026 margins in the mid-20% range

Lexington, MA, August 7, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the second quarter ended June 30, 2026.
"Our second quarter results reflect continued execution against the strategic and financial priorities we outlined at the beginning of the year," said Robert Spignesi, President and CEO. "Total revenue increased 11%, recurring revenue grew 14% and consumables achieved quarterly records in both units and revenue. Importantly, we delivered record second-quarter total gross margin of 15%, marking a positive inflection that reflects meaningful progress against our margin expansion initiatives and supports our path to positive cash flow."
Spignesi continued, "As we look to the second half of 2026, we remain encouraged by strong customer engagement, continued momentum in multi-system and enterprise deployment opportunities, and an expanding contribution from our collaboration with MilliporeSigma. Combined with favorable industry tailwinds, including increased adoption of automation and ongoing U.S. reshoring and biomanufacturing capacity expansion, we believe we are well positioned to achieve our full-year objectives and enter 2027 with positive momentum."
Second Quarter Financial Results
Total revenue for the second quarter of 2026 increased 10.9% to $8.1 million compared to $7.3 million in the second quarter of 2025. The Company placed four new Growth Direct® systems and completed the validation of nine customer systems compared to four placements and two validations in the second quarter of 2025. Product revenue increased 10.1% to $5.3 million, compared to $4.8 million in the second quarter of 2025. Service revenue increased 12.5% to $2.8 million, compared to $2.5 million in the second quarter of 2025. Recurring revenue increased 14.3% to $5.0 million, compared to $4.4 million in the second quarter of 2025.
Total cost of revenue was $6.8 million in the second quarter of 2026, a decrease of 2.1% compared to $7.0 million in the second quarter of 2025. Gross margin was 15.0%, or $1.2 million, a quarterly record, compared to 3.8%, or $0.3 million in the second quarter of 2025.
Total operating expenses increased by 8.9% to $13.5 million in the second quarter of 2026, compared to $12.4 million in the second quarter of 2025. General and administrative expenses increased by 11.3%, research and development


expenses increased by 3.2%, and sales and marketing expenses increased by 10.3%, in each case compared to the second quarter of 2025.
Net loss for the second quarter of 2026 was $12.9 million and net loss per share was $0.27, compared to a net loss of $11.9 million and net loss per share of $0.27 in the second quarter of 2025.
Non-GAAP adjusted EBITDA loss for the second quarter of 2026 was $10.3 million, compared to a loss of $10.1 million in the second quarter of 2025.
Cash, cash equivalents, and short-term investments were approximately $20 million as of June 30, 2026.
Full Year 2026 Outlook
The Company is reaffirming its full year 2026 total revenue guidance range of $37.0 million to $41.0 million including a range of 30 to 38 Growth Direct system placements and total gross margin percentage of approximately 20%. The Company is increasing its full year 2026 system validation guidance to at least 27 validations, up from 25 previously.
Webcast Details
The Company will host a conference call before the market opens today, August 7, 2026, at 8:30 a.m. ET to discuss its second quarter 2026 financial results. The live call is accessible on the Company’s website at investors.rapidmicrobio.com and will be archived and available for replay for one year.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered in Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.
Rapid Micro Biosystems intends to use the Investor Relations page of its website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor its website in addition to following press releases, filings with the Securities and Exchange Commission (“SEC”), public conference calls, presentations and webcasts.
Non-GAAP Financial Measures
In addition to reporting financial measures in accordance with generally accepted accounting principles (“GAAP”), the Company is including in this press release "non-GAAP adjusted EBITDA," which is a non-GAAP financial measure. The Company defines non-GAAP adjusted EBITDA as net loss excluding interest income, interest expense, other expense, net, income tax expense, depreciation and amortization, and stock-based compensation.
The Company includes this non-GAAP financial measure because it believes it allows investors to understand and evaluate the Company’s core operating performance and trends. In particular, the exclusion of certain items in calculating non-GAAP adjusted EBITDA can provide useful measures for period-to-period comparisons of the Company’s core business. This non-GAAP financial measure has limitations as an analytical tool, including the fact that such non-GAAP financial measure may not be comparable to a similarly titled measure presented by other companies because other companies may calculate non-GAAP EBITDA differently than the Company does. For more information regarding this non-GAAP financial measure, see the table included at the end of this press release.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the Company’s guidance, including with respect to full year 2026 total revenue, gross


margin, number of Growth Direct placements and system validations; statements regarding the Company's achievement of its full year objectives, and the Company's growth outlook in future periods.

In some cases, you can identify forward-looking statements by terminology such as “outlook,” “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including, but not limited to risks related to, the Company's ability to achieve positive cash flow; the Company's ability to achieve its business objectives; the Company's significant losses since inception; the Company’s ability to meet its publicly announced guidance and other expectations about its business and operations; the Company's ability to fulfill customer orders on its anticipated timelines or at all; the impact of the Company's existing and any future indebtedness on its ability to operate its business; the Company’s ability to access any future tranches under its debt facility and to comply with all of its obligations thereunder; the Company’s limited experience in marketing and sales and the effectiveness of its sales processes; the Company’s need to develop new products and adapt to technological changes; the Company’s ability to establish and maintain its position as a leading provider of automated microbial quality control testing; the Company’s ability to maintain its manufacturing facility; the Company's ability to improve the gross margins of its products and services; risks related to third-parties; the Company’s ability to retain key management and other employees; risks related to regulatory and intellectual property matters; risks related to supply chain disruptions and the impact of inflation; risks associated with macroeconomic events and uncertainty, including with respect to tariff and trade policy in the U.S. and abroad, as well as activity in the Company's industry and in the general economy; and the other important factors outlined under the caption “Risk Factors” in the Company’s Quarterly Report on Form 10-Q filed with the SEC, as such factors may be updated from time to time in its other filings with the SEC, which are available on the SEC's website at www.sec.gov and the Investor Relations page of its website at investors.rapidmicrobio.com. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.
Investor Contact
Michael Beaulieu, CFA
Vice President, Investor Relations and Corporate Communications
investors@rapidmicrobio.com
Media Contact
media@rapidmicrobio.com



RAPID MICRO BIOSYSTEMS, INC.
Unaudited Condensed Consolidated Statements of Operations
(in thousands, except share and per share amounts)

Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Revenue:
Product revenue$5,286 $4,802 $10,864 $8,903 
Service revenue2,768 2,460 5,192 5,564 
Total revenue8,054 7,262 16,056 14,467 
Cost of revenue:
Cost of product revenue5,434 5,315 11,459 10,344 
Cost of service revenue1,408 1,672 3,014 3,444 
Total cost of revenue6,842 6,987 14,473 13,788 
Gross margin1,212 275 1,583 679 
Operating expenses:
Research and development3,332 3,230 6,691 6,854 
Sales and marketing3,436 3,114 6,858 5,865 
General and administrative6,766 6,079 14,208 11,769 
Total operating expenses13,534 12,423 27,757 24,488 
Loss from operations(12,322)(12,148)(26,174)(23,809)
Other income (expense):
Interest income140 351 396 817 
Interest expense(646)(12)(1,285)(24)
Other expense, net(50)(38)(82)(87)
Total other income (expense), net(556)301 (971)706 
Loss before income taxes(12,878)(11,847)(27,145)(23,103)
Income tax expense45 11 53 18 
Net loss$(12,923)$(11,858)$(27,198)$(23,121)
Net loss per share — basic and diluted$(0.27)$(0.27)$(0.58)$(0.52)
Weighted average common shares outstanding — basic and diluted48,346,66344,648,60247,008,32244,321,566


RAPID MICRO BIOSYSTEMS, INC.
Unaudited Condensed Consolidated Balance Sheets
(in thousands)
June 30,
2026		December 31,
2025
Assets
Current assets:
Cash and cash equivalents$14,687 $20,030 
Short-term investments5,079 18,266 
Accounts receivable5,515 3,134 
Inventory, net18,918 17,593 
Prepaid expenses and other current assets2,063 2,145 
Total current assets46,262 61,168 
Property and equipment, net8,161 8,972 
Right-of-use assets3,565 4,109 
Other long-term assets178 319 
Restricted cash284 284 
Total assets58,450 74,852 
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable$5,177 $4,139 
Accrued expenses and other current liabilities6,123 8,316 
Deferred revenue5,508 4,734 
Lease liabilities, short-term1,342 1,298 
Total current liabilities18,150 18,487 
Lease liabilities, long-term2,997 3,674 
Notes payable, net19,139 18,902 
Warrant liability68 186 
Other long-term liabilities348 397 
Total liabilities40,702 41,646 
Total stockholders’ equity17,748 33,206 
Total liabilities and stockholders’ equity$58,450 $74,852 




RAPID MICRO BIOSYSTEMS, INC.
Unaudited Cash, Cash Equivalents and Investments
(in thousands)

June 30,
2026		December 31,
2025
Cash and cash equivalents$14,687 $20,030 
Short-term investments5,079 18,266 
Restricted cash
284 284 
Cash, cash equivalents, investments and restricted cash$20,050 $38,580 



RAPID MICRO BIOSYSTEMS, INC.
Unaudited net Loss to Non-GAAP Adjusted EBITDA Loss Reconciliation
(in thousands)

Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Net loss$(12,923)$(11,858)$(27,198)$(23,121)
Interest income(140)(351)(396)(817)
Interest expense646 12 1,285 24 
Other expense, net50 38 82 87 
Income tax expense45 11 53 18 
Depreciation and amortization674 811 1,380 1,658 
Stock-based compensation1,321 1,218 2,544 2,260 
Non-GAAP adjusted EBITDA loss$(10,327)$(10,119)$(22,250)$(19,891)

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Press Releases

Other Documents